Monitor for the closing of the merger with Mentari Therapeutics, which remains subject to conditions. The creation of Series A Preferred Shares with conversion rights and board representation rights introduces potential future dilution and governance changes. The CVR issuance adds a contingent value component for existing shareholders.
INM drugs
INM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 5 $13.21entry
- T+1 · 11d ago +17.79%α +17.48% · $15.56
- T+5 · due 5d ago Pending
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
InMed Pharmaceuticals Inc. held its annual general and special meeting on November 4, 2026, where shareholders approved all proposals related to the pending merger with Mentari Therapeutics, including the Nasdaq share issuance, redomestication to Nevada, and the new stock incentive plan. The company also completed a 1-for-10 reverse stock split, changed its name to Mentari Therapeutics, Inc., and created a new series of non-voting convertible preferred shares (Series A Preferred) as part of the merger process.
Key Facts
- Shareholders approved the Nasdaq share issuance proposal with 97.295% of votes for, authorizing the issuance of common shares representing more than 20% of outstanding shares to Mentari stockholders.
- Shareholders approved the redomestication from British Columbia to Nevada with 88.825% of votes for.
- Shareholders approved the Mentari Therapeutics 2026 Stock Incentive Plan with 88.615% of votes for.
- The company completed a 1-for-10 reverse stock split, reducing outstanding common shares from 5,493,735 to approximately 549,374.
- The company changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc., effective November 4, 2026.
- The company created 4,013 Series A Non-Voting Preferred Shares, each convertible into 1,000 common shares, subject to a 19.99% beneficial ownership limitation.
- All five director nominees were elected with over 89% of votes for each.
- Shareholders approved the re-appointment of CBIZ CPAs P.C. as auditor with 95.943% of votes for.
- The company expects to issue one contingent value right (CVR) per post-consolidation common share to holders of record as of November 5, 2026, contingent on future events.
- The merger closing remains subject to satisfaction or waiver of remaining conditions.
Financial Impact
No financial figures disclosed in the filing. The reverse stock split reduced share count from 5,493,735 to approximately 549,374, with no change in proportionate equity.
Risk Factors
- The merger may not close on the anticipated timeline or at all if conditions are not satisfied or waived.
- The Series A Preferred Shares, if converted, could result in significant dilution to common shareholders (up to 4,013,000 common shares).
- The beneficial ownership limitation on conversion of Series A Preferred Shares may be waived or changed by holders with 61 days notice, potentially increasing dilution risk.
- The CVR payments are contingent on future events and may never materialize.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-448367 |
| Document: d173223d8k.htm | 0001193125-26-448367 |
| Document: d173223dex991.htm | 0001193125-26-448367 |
| Document: d173223dex31.htm | 0001193125-26-448367 |
| Document: 0001193125-26-448367-index-headers.html | 0001193125-26-448367 |
| Document: 0001193125-26-448367-index.html | 0001193125-26-448367 |
| Document: 0001193125-26-448367.txt | 0001193125-26-448367 |
Track record
22 reports on INM
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers